MA34030B1 - Formulations pharmaceutiques solides comprenant du bibw 2992 - Google Patents

Formulations pharmaceutiques solides comprenant du bibw 2992

Info

Publication number
MA34030B1
MA34030B1 MA33400A MA33400A MA34030B1 MA 34030 B1 MA34030 B1 MA 34030B1 MA 33400 A MA33400 A MA 33400A MA 33400 A MA33400 A MA 33400A MA 34030 B1 MA34030 B1 MA 34030B1
Authority
MA
Morocco
Prior art keywords
bibw
active substance
tablets
prepared
image
Prior art date
Application number
MA33400A
Other languages
Arabic (ar)
English (en)
Inventor
Roman Messerschmid
Thomas Friedl
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40941955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34030(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA34030B1 publication Critical patent/MA34030B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne une forme de dosage pharmaceutique qui contient la substance active bibw 2992 sous forme d'un sel de dimaléate, permettant d'obtenir un profil de libération immédiate de la substance active. L'invention concerne en outre des intermédiaires compactés qui comprennent un sel de dimaléate de bibw 2992 (bibw 2992 ma2) sous la forme d'une poudre préparée en utilisant une étape combinée de compactage à rouleaux et de tamisage du bibw 2992 ma2, des mélanges intermédiaires préparés à partir dudit intermédiaire compacté, ainsi que des formulations orales solides permettant d'obtenir un profil de libération immédiate de la substance active, préparées à partir dudit intermédiaire compacté ou desdits mélanges d'intermédiaires prêts pour utilisation/ingestion, par ex., des formulations en capsules ou en comprimés telles que des comprimés nus ou pelliculés préparés par compression directe, et des procédés pour leur production.
MA33400A 2008-06-06 2009-06-05 Formulations pharmaceutiques solides comprenant du bibw 2992 MA34030B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08157800 2008-06-06
EP09160297 2009-05-14
PCT/EP2009/056944 WO2009147238A1 (fr) 2008-06-06 2009-06-05 Formulations pharmaceutiques solides comprenant du bibw 2992

Publications (1)

Publication Number Publication Date
MA34030B1 true MA34030B1 (fr) 2013-03-05

Family

ID=40941955

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33400A MA34030B1 (fr) 2008-06-06 2009-06-05 Formulations pharmaceutiques solides comprenant du bibw 2992

Country Status (33)

Country Link
US (1) US8545884B2 (fr)
EP (1) EP2299971B1 (fr)
JP (1) JP5632367B2 (fr)
KR (1) KR101641517B1 (fr)
CN (1) CN102056589B (fr)
AR (1) AR072062A1 (fr)
AU (1) AU2009254574B2 (fr)
BR (1) BRPI0913379C1 (fr)
CA (1) CA2726472C (fr)
CL (1) CL2010001275A1 (fr)
CO (1) CO6280463A2 (fr)
CY (1) CY1117895T1 (fr)
DK (1) DK2299971T3 (fr)
EA (1) EA022168B1 (fr)
EC (1) ECSP10010650A (fr)
ES (1) ES2588031T3 (fr)
HR (1) HRP20161061T1 (fr)
HU (1) HUE029863T2 (fr)
IL (1) IL209054A (fr)
MA (1) MA34030B1 (fr)
ME (1) ME02478B (fr)
MX (1) MX2010012939A (fr)
MY (1) MY151240A (fr)
NZ (1) NZ589568A (fr)
PE (1) PE20100252A1 (fr)
PL (1) PL2299971T3 (fr)
PT (1) PT2299971T (fr)
RS (1) RS54943B1 (fr)
SI (1) SI2299971T1 (fr)
TW (1) TWI453203B (fr)
UY (1) UY31867A (fr)
WO (1) WO2009147238A1 (fr)
ZA (1) ZA201007805B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE04748B1 (et) 1999-06-21 2006-12-15 Boehringer Ingelheim Pharma Kg Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10221018A1 (de) * 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
PL1948180T3 (pl) * 2005-11-11 2013-09-30 Boehringer Ingelheim Int Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2
CA2833706C (fr) * 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Derives de quinazoline pour le traitement des affections cancereuses
JP5241513B2 (ja) * 2006-01-26 2013-07-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アミノクロトニルアミノ置換キナゾリン誘導体の合成方法
AU2007299080B2 (en) * 2006-09-18 2013-04-18 Boehringer Ingelheim International Gmbh Method for treating cancer harboring EGFR mutations
PE20100252A1 (es) 2008-06-06 2010-04-12 Boehringer Ingelheim Int Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
PL2451445T3 (pl) 2009-07-06 2019-09-30 Boehringer Ingelheim International Gmbh Sposób suszenia BIBW2992, jego soli i stałych preparatów farmaceutycznych zawierających tę substancję czynną
PT2608792T (pt) 2010-08-26 2018-01-15 Boehringer Ingelheim Int Métodos de administração de um inibidor de egfr
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
EP2951171A1 (fr) 2013-02-01 2015-12-09 Boehringer Ingelheim International GmbH Dérivés de quinazoline radiomarqués
CN104540820B (zh) * 2013-07-16 2016-12-21 杭州普晒医药科技有限公司 阿法替尼酸加成盐及其晶型、其制备方法及药物组合物
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
NO2699580T3 (fr) 2014-01-24 2018-02-24
CN105534920B (zh) * 2014-10-29 2020-07-10 江苏豪森药业集团有限公司 一种药物组合物及其制备方法
EP3023421A1 (fr) 2014-11-21 2016-05-25 Sandoz Ag Formes cristallines de dimaléate d'afatinib
CN105769804B (zh) * 2014-12-23 2019-04-30 上海复星星泰医药科技有限公司 一种阿法替尼片及其制备方法
CN105801568B (zh) 2015-01-15 2019-07-30 杭州普晒医药科技有限公司 阿法替尼一马来酸盐晶型及其制备方法和药物组合物
KR20180018551A (ko) 2015-06-12 2018-02-21 프레세니어스 카비 온콜로지 리미티드 아파티닙 유리 염기 및 아파티닙 디말레에이트의 다형체 형태
EP3337461A1 (fr) 2015-08-21 2018-06-27 Fresenius Kabi Oncology Ltd Compositions pharmaceutiques comportant de l'afatinib
EP3156047A1 (fr) * 2015-10-12 2017-04-19 Sandoz Ag Formulation contenant de l'afatinib
CN105456222B (zh) * 2015-12-22 2019-03-26 河南润弘制药股份有限公司 马来酸阿法替尼片及其制备方法
EP3260115A1 (fr) * 2016-06-21 2017-12-27 Omya International AG Procédé pour la production d'une forme posologique
EP3260114A1 (fr) * 2016-06-21 2017-12-27 Omya International AG Procédé pour la production d'une forme posologique
CN106074427A (zh) * 2016-07-31 2016-11-09 合肥远志医药科技开发有限公司 一种马来酸阿法替尼片剂及其制备方法
MA46852A (fr) 2016-11-17 2019-09-25 Univ Texas Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20
US20180206528A1 (en) * 2017-01-24 2018-07-26 Omnigen Research, Llc Granulated feed supplement and methods for making and using
WO2018187643A1 (fr) 2017-04-06 2018-10-11 Johnson Matthey Public Limited Company Nouvelles formes de dimaléate d'afatinib
WO2019070698A1 (fr) 2017-10-02 2019-04-11 Johnson Matthey Public Limited Company Nouvelles formes d'ibrutinib
KR20250002710A (ko) 2018-03-01 2025-01-07 아스트라제네카 에이비이 (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를포함하는 약학 조성물
WO2019195827A1 (fr) 2018-04-06 2019-10-10 Johnson Matthey Public Limited Company Nouvelle forme d'ibrutinib
WO2019209908A1 (fr) 2018-04-25 2019-10-31 Johnson Matthey Public Limited Company Formes cristallines de dasatinib
AU2019306532A1 (en) 2018-07-17 2021-03-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis
EP4646265A1 (fr) 2023-01-06 2025-11-12 Insmed Incorporated Nouveaux inhibiteurs de dpp1 réversibles et leurs utilisations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE04748B1 (et) 1999-06-21 2006-12-15 Boehringer Ingelheim Pharma Kg Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
US20030225079A1 (en) 2002-05-11 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
PL1948180T3 (pl) 2005-11-11 2013-09-30 Boehringer Ingelheim Int Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2
CA2833706C (fr) * 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Derives de quinazoline pour le traitement des affections cancereuses
JP5241513B2 (ja) 2006-01-26 2013-07-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アミノクロトニルアミノ置換キナゾリン誘導体の合成方法
US8338416B2 (en) * 2006-03-16 2012-12-25 Pharmacylics, Inc. Indole derivatives as inhibitors of histone deacetylase
AU2007299080B2 (en) 2006-09-18 2013-04-18 Boehringer Ingelheim International Gmbh Method for treating cancer harboring EGFR mutations
PE20100252A1 (es) 2008-06-06 2010-04-12 Boehringer Ingelheim Int Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
JP2012515184A (ja) 2009-01-14 2012-07-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大腸がんの治療方法
PL2451445T3 (pl) 2009-07-06 2019-09-30 Boehringer Ingelheim International Gmbh Sposób suszenia BIBW2992, jego soli i stałych preparatów farmaceutycznych zawierających tę substancję czynną
JP2013512882A (ja) 2009-12-07 2013-04-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング トリプルネガティブ乳癌の治療に使用するｂｉｂｗ２９９２

Also Published As

Publication number Publication date
CY1117895T1 (el) 2017-05-17
DK2299971T3 (en) 2016-08-29
CA2726472C (fr) 2017-10-03
CN102056589A (zh) 2011-05-11
AR072062A1 (es) 2010-08-04
RS54943B1 (sr) 2016-11-30
BRPI0913379A2 (pt) 2015-11-24
HRP20161061T1 (hr) 2016-10-21
ECSP10010650A (es) 2011-02-28
MX2010012939A (es) 2010-12-15
US8545884B2 (en) 2013-10-01
IL209054A (en) 2015-07-30
EA022168B1 (ru) 2015-11-30
KR101641517B1 (ko) 2016-07-29
TWI453203B (zh) 2014-09-21
HUE029863T2 (en) 2017-04-28
NZ589568A (en) 2012-08-31
MY151240A (en) 2014-04-30
PL2299971T3 (pl) 2017-04-28
CN102056589B (zh) 2013-09-25
PT2299971T (pt) 2016-07-29
CA2726472A1 (fr) 2009-12-10
TW201000472A (en) 2010-01-01
EP2299971B1 (fr) 2016-05-25
EP2299971A1 (fr) 2011-03-30
SI2299971T1 (sl) 2016-09-30
BRPI0913379B1 (pt) 2020-03-31
ME02478B (fr) 2017-02-20
ZA201007805B (en) 2011-07-27
CO6280463A2 (es) 2011-05-20
AU2009254574B2 (en) 2014-07-03
BRPI0913379B8 (pt) 2021-03-30
HK1152478A1 (en) 2012-03-02
US20110142929A1 (en) 2011-06-16
AU2009254574A1 (en) 2009-12-10
PE20100252A1 (es) 2010-04-12
ES2588031T3 (es) 2016-10-28
CL2010001275A1 (es) 2011-05-13
IL209054A0 (en) 2011-01-31
JP2011522011A (ja) 2011-07-28
WO2009147238A1 (fr) 2009-12-10
UY31867A (es) 2010-01-29
KR20110025908A (ko) 2011-03-14
BRPI0913379C1 (pt) 2021-05-25
JP5632367B2 (ja) 2014-11-26
EA201001852A1 (ru) 2011-06-30

Similar Documents

Publication Publication Date Title
MA34030B1 (fr) Formulations pharmaceutiques solides comprenant du bibw 2992
MX359229B (es) Forma de dosificación farmacéutica en cápsula que comprende una formulación en suspensión de un derivado de indolinona.
JP2014005302A5 (fr)
NO20083104L (no) Fast preparat
NO20060946L (no) β-krystallinsk form av ivabradin-hydroklorid, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20060947L (no) β d-krystalinsk form av ivabradin-hydroklorid, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
IL179718A0 (en) Pharmaceutical composition containing irbesartan
EA201290985A1 (ru) Пероральные ветеринарные фармацевтические и нутрицевтические композиции
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
TW201129386A (en) Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
WO2009120389A8 (fr) Préparations orales et injectables de composés de tétracycline
NO20084478L (no) Konjugerte lipidderivater
EA200700158A1 (ru) Лекарственные формы с ядром таблетки, покрытым энтеросолюбильной оболочкой
JP2023052398A (ja) ４－アミノ－３－ブタン酸類縁体含有固形製剤
WO2007120838A3 (fr) Forme pharmaceutique orale, solide et à désintégration rapide, de dispersions liquides
EA201001108A1 (ru) Диспергируемые во рту таблетки, содержащие основание эсциталопрама, и способ их получения
WO2009120844A3 (fr) Compositions pharmaceutiques comprenant un sensibilisateur à l’insuline et un secrétagogue d’insuline
WO2005115346A3 (fr) Composition contenant de la risperidone
WO2007009691A3 (fr) Combinaison de substances active s
WO2009004039A3 (fr) Formulation
ATE457721T1 (de) An titandioxidnanopartikeln absorbierte pharmazeutische wirkstoffe enthaltende pharmazeutische formulierungen
NO20084524L (no) Farmasoytisk sammensetning inneholdende NMB0938-protein
JP2018530537A5 (fr)
JPWO2017142001A1 (ja) 口腔内速崩壊性錠剤用造粒物
JP2017052778A5 (fr)